We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
BOLT

Price
5.44
Stock movement down
-0.42 (-7.17%)
Company name
Bolt Biotherapeutics
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
10.44M
Ent value
25.64M
Price/Sales
0.36
Price/Book
0.33
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-12.58%
1 year return
852.55%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-12-12

DIVIDENDS

BOLT does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales0.36
Price to Book0.33
EV to Sales0.88

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count1.92M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)-20.24

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash17.75M
Net receivables0.00
Total current assets35.61M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment28.51M
Total assets65.05M
Accounts payable1.52M
Short/Current long term debt23.59M
Total current liabilities9.97M
Total liabilities32.95M
Shareholder's equity32.10M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open5.85
Daily high6.15
Daily low5.40
Daily Volume74K
All-time high39.93
1y analyst estimate22.00
Beta0.92
EPS (TTM)-
Dividend per share0.00
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
BOLTS&P500
Current price drop from All-time high-86.38%-1.08%
Highest price drop-99.27%-19.00%
Date of highest drop16 May 20258 Apr 2025
Avg drop from high-93.12%-2.64%
Avg time to new high-6 days
Max time to new high296 days89 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
BOLT (Bolt Biotherapeutics) company logo
Marketcap
10.44M
Marketcap category
Small-cap
Description
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Employees
40
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...